RT Journal Article
SR Electronic
T1 Inferring the COVID-19 IFR with a simple Bayesian evidence synthesis of seroprevalence study data and imprecise mortality data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.12.21256975
DO 10.1101/2021.05.12.21256975
A1 Campbell, Harlan
A1 Gustafson, Paul
YR 2021
UL http://medrxiv.org/content/early/2021/05/13/2021.05.12.21256975.abstract
AB Estimating the COVID-19 infection fatality rate (IFR) has proven to be particularly challenging –and rather controversial– due to the fact that both the data on deaths and the data on the number of individuals infected are subject to many different biases. We consider a Bayesian evidence synthesis approach which, while simple enough for researchers to understand and use, accounts for many important sources of uncertainty inherent in both the seroprevalence and mortality data. We estimate the COVID-19 IFR to be 0.38% (95% prediction interval of (0.03%, 1.19%)) for a typical population where the proportion of those aged over 65 years old is 9% (the approximate worldwide value). Our results suggest that, despite immense efforts made to better understand the COVID-19 IFR, there remains a large amount of uncertainty and unexplained heterogeneity surrounding this important statistic.Above all, what’s needed is humility in the face of an intricately evolving body of evidence. The pandemic could well drift or shift into something that defies our best efforts to model and characterize it.Siddhartha Mukherjee, The New YorkerFebruary 22, 2021Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the European Union's Horizon 2020 research and innovation programme under ReCoDID grant agreement No 825746 and by the Canadian Institutes of Health Research, Institute of Genetics (CIHR-IG) under Grant Agreement No 01886-000.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB review was necessary for this retrospective analysis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data collected for the analysis is available at: https://tinyurl.com/awskkwkn